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Abstract
Bullous systemic lupus erythematosus is a rare blistering condition with a distinctive combination
of clinical, histological and immunopathologic features that together constitute a unique bullous
disease phenotype. It is often associated with autoimmunity to type VII collagen. Here we report a
child who presented with bullous systemic lupus erythematosus. Rapid resolution of the blisters
occurred following treatment with dapsone.
Introduction
Bullous systemic lupus erythematosus (SLE) is a rare, dis-
tinctive subepidermal blistering disorder that occurs in
systemic lupus erythematosus [1]. It is characterized clin-
ically by a pemphigoid-like eruption with tense fluid-
filled vesicles and bullae, often with a background of mac-
ulopapular or urticated erythema. It can affect any area of
the body, including non-sun-exposed sites and the
mucous membranes. Pruritus is usually present in varia-
ble severity. The lesions form erosions and crusts before
healing, usually but not invariably without scarring. Treat-
ment with dapsone results in promising results. We
describe a 13 years old girl who presented with bullous
SLE.
Case presentation
A 13-year-old girl presented with recurrent fever associ-
ated with increasing fatigue, arthraliga, hair loss and ery-
thematosus bullous lesions over face, neck and
extremities of 2 months duration. She also had one epi-
sode of generalised tonic clonic seizures prior to admis-
sion.
She was treated with oral antibiotics and topical hydrocor-
tisone for her skin lesions. On examination she had
numerous bullae and vesicles on a background of urti-
cated plaques affecting the back, abdomen, neck and flex-
ures of the arm and groin regions (Fig. 1). Nikolsky's sign
was negative. Erosions with crusts characterized older
lesions. No scarring was seen at the sites of healed lesions.
There were no mucosal erosions or blisters. No malar rash
or oral ulcers. No raynaud's phenomenon. Cardiovascular
and respiratory system examination were within normal
limits. Abdominal examination did not reveal hepat-
osplenomegaly. Her fundoscopy did not reveal evidence
of hypertensive encephalopathy or vasculitis. Otherwise
neurologically she was normal.
Investigations revealed hemoglobin was 90 g/L, white
blood cell was 21 × 109/L with neutrophils of 2.5 × 109/L,
lymphocytes of 1 × 109/L, bands 0.03 × 109/L. Her plate-
lets were 20 × 109/L. Her INR and PTT were within normal
limits. ESR was 55 mm at 1 hour and CRP was negative.
Her serum creatinine was 42 μmol/L. ANA was positive in
1/640 titers with speckled pattern and DsDNA was ele-
vated. Complements (C3 and C4) were low. Anticardioli-
pin antibody and lupus anticoagulant were negative. Anti-
Ro, anti-La, anti-Sm antibodies were also negative. Urine
microscopy showed microscopic hematuria and proteinu-
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ria. 24 hour urinary protein was 20 mg/m2/hr. CSF analy-
sis was within normal limits including opening pressure.
Skin biopsy from these bullous lesions revealed a neu-
trophil-predominant inflammatory infiltrate in the upper
dermis with dermal-epidermal separation. Direct immun-
ofluorescence (DIF) showed prominent fluorescence
along the epidermal basement membrane for IgG, IgA,
IgM and C3. There was also smudgy fluorescence rimming
some of the dermal blood vessels for IgA, IgM & C3. She
was diagnosed to have Bullous SLE with renal and CNS
involvement. Renal biopsy was deferred in view of throm-
bocytopenia.
She was treated with prednisolone 2 mg/kg/day and dap-
sone 50 mg for her skin lesions. She was also administered
cyclophosphamide 500 mg/m2 as infusion with hydra-
tion. Her skin lesions improved within a week. As parents
wanted to try alternative medicine, she was discharged at
request.
Discussion
Bullous systemic lupus erythematosus (BSLE) is a rare,
chronic, non-scarring blistering eruption, characterized by
subepidermal blisters with acute predominantly neu-
trophilic inflammation in the upper dermis, immune
complex linear deposition at the basement membrane by
immunofluorescence, and immune deposits beneath the
lamina densa by ultrastructural analysis [2]. Less than 5%
patients with SLE develop vesiculobullous lesions in iso-
lation or in addition to other cutaneous manifestations
[3].
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Blisters in SLE can be due to bullous SLE or SLE with blis-
ters. Histologically, bullous SLE is a subepidermal blister-
ing disease with an acute neutrophil-predominant
infiltrate in the upper dermis. In contrast, the histology of
cutaneous lesions of SLE with blistering reveals severe
edema in the upper dermis and hydropic degeneration of
the basal layer. Epidermal necrosis is seen at the advanc-
ing edges of the lesions [4].
DIF of bullous SLE demonstrates linear or granular depo-
sition of IgG (with or without IgA and/or IgM) and com-
plement deposition at the basement membrane zone.
Indirect immunofluorescence (IIF) of serum may demon-
strate circulating antibodies to type VII collagen. These
antibodies usually demonstrate binding to the dermal
side of salt-split skin preparations on IIF. Our child did
not have IIF. These antibodies are thought to be patho-
genic because type VII collagen is a major component of
the anchoring fibril, which has a central role in the gener-
ation of basement membrane-dermal adhesion. It is
thought that immune complexes binding to type VII col-
lagen or complement mediated damage to type VII colla-
gen impairs anchoring fibril function and leads to
subepidermal blister formation [5].
The precise delineation of bullous SLE from several pri-
mary blistering disorders (eg, bullous pemphigoid, der-
matitis herpetiformis, pemphigus vulgaris, epidermolysis
bullosa acquisita) is based on [1] widespread cutaneous
vesiculobullous eruption [2] histology of skin lesions
demonstrating acute neutrophilic upper dermal infiltrate
and subepidermal separation [3] a positive direct or indi-
rect immunofluorescence test demonstrating antibodies
directed against the basement membrane [4] a tendency
to respond to treatment with dapsone and [5] the pres-
ence of autoantibodies to type VII collagen as seen in epi-
dermolysis bullosa acquisita (EBA).
Dapsone is the mainstay of treatment of bullous SLE [6].
Bullous lupus often responds dramatically to dapsone,
usually with ceasing of the formation of new lesions
within 12–48 h after initiation of therapy and with heal-
ing of old lesions within several days. Relatively low doses
(25–50 mg daily) may be efficacious in some cases. Rapid
recurrences may occur upon withdrawal of dapsone, with
prompt remission after reinstitution of therapy [7]. Meth-
otrexate is also efficacious in management of bullous SLE
[8]. Azathioprine, antimalarials and cyclophosphamide
have been used as steroid-sparing agents in those cases
unresponsive to dapsone. The disease usually remits,
often within 1 year.
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